Yahoo Finance • 18 days ago
(RTTNews) - Patience is a virtue - important in all aspects of life, and especially crucial when it comes to investing. As trading expert Steve Burns once said, "Much of our trading comes down to a battle between our patience and our impul... Full story
Yahoo Finance • 21 days ago
[Patent] JLGutierrez Arrowhead Pharmaceuticals (NASDAQ:ARWR [https://seekingalpha.com/symbol/ARWR]) sued Ionis Pharmaceuticals (NASDAQ:IONS [https://seekingalpha.com/symbol/IONS]) in a Delaware District Court on Wednesday as part of a pat... Full story
Yahoo Finance • 23 days ago
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the Best Stocks to Buy for the Next 3 Months According to Hedge Funds. On September 2, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc.... Full story
Yahoo Finance • 27 days ago
We came across a bullish thesis on Medpace Holdings, Inc. on Rocky&Turner’s Substack by James Emanuel. In this article, we will summarize the bulls’ thesis on MEDP. Medpace Holdings, Inc. 's share was trading at $475.51 as of August 29th.... Full story
Yahoo Finance • 29 days ago
This article first appeared on GuruFocus. Sep 3 - Alphabet (NASDAQ:GOOGL) jumped on Wednesday, rising more than 7%, as investors reacted to a favorable antitrust ruling. A federal judge decided Google would not be forced to divest its Chr... Full story
Yahoo Finance • last month
- Upon closing, Arrowhead will receive an upfront payment of $200 million - Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the treatment of synucleinopathies, such as Park... Full story
Yahoo Finance • last month
Investing.com - Mizuho maintained its Neutral rating and $19.00 price target on Sarepta Therapeutics (NASDAQ:SRPT) following the company’s second-quarter 2025 earnings report and debt refinancing. The stock, currently trading at $20.22,... Full story
Yahoo Finance • last month
We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by 24.9 percent week-on-week as investor... Full story
Yahoo Finance • 2 months ago
- Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 million milestone payment - Sarepta sells at least $174 million of Arrowhead common s... Full story
Yahoo Finance • 2 months ago
- Arrowhead has elected to receive approximately $50 million worth of Arrowhead common stock from Sarepta, which will be placed into treasury and reduce the number of Arrowhead shares outstanding - The remainder of the recently earned $10... Full story
Yahoo Finance • 2 months ago
Investing.com - TD Cowen has reiterated its Hold rating and $17.00 price target on Sarepta Therapeutics (NASDAQ:SRPT), whose shares have fallen over 85% in the past year, following the company’s first Duchenne muscular dystrophy (DMD) pa... Full story
Yahoo Finance • 2 months ago
Investing.com - Leerink Partners has lowered its price target on Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $21.00 from $22.00 while maintaining a Market Perform rating following the company’s fiscal third-quarter 2025 results. The stock,... Full story
Yahoo Finance • 2 months ago
[Stock market concept] Mikko Lemola The S&P500 (SP500 [https://seekingalpha.com/symbol/SP500#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link%7Cfirst_level_url%3Anews]) closed in the red on Friday after the we... Full story
Yahoo Finance • 2 months ago
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market... Full story
Yahoo Finance • 2 months ago
Investing.com - Bernstein SocGen Group initiated coverage on Sarepta Therapeutics (NASDAQ:SRPT) with a Market Perform rating and a $13.00 price target on Tuesday, as the company approaches its next earnings release on July 30. The ratin... Full story
Yahoo Finance • 2 months ago
Arrowhead Pharmaceuticals (NASDAQ:ARWR [https://seekingalpha.com/symbol/ARWR]) Monday announced [https://seekingalpha.com/pr/20179072-arrowhead-pharmaceuticals-earns-100-million-milestone-from-sarepta-therapeutics] that it has earned a $10... Full story
Yahoo Finance • 2 months ago
Investing.com - Barclays downgraded Sarepta Therapeutics (NASDAQ:SRPT) from Equalweight to Underweight and slashed its price target to $10.00 from $18.00 on Monday. The stock, currently trading at $11.93, has plummeted 90% year-to-date a... Full story
Yahoo Finance • 2 months ago
Wednesday’s market has seen significant activity, with stocks like Eli Lilly And Co (NYSE:LLY) and GE Vernova LLC (GEV) experiencing notable increases, while Fiserv Inc (NYSE:FI) (FISV) faced a sharp decline. These movements reflect a... Full story
Yahoo Finance • 2 months ago
Monday’s trading session is showcasing notable movements across various stock categories, with mega-caps like Google Inc (NASDAQ:GOOGL) and Linde AG (ETR:LING) (LIN) experiencing positive shifts, while large-cap stocks such as Astera L... Full story
Yahoo Finance • 2 months ago
Check out the companies making the biggest moves midday: Bruker — The lab instrument and tools maker shed 12% after the company issued weaker-than-expected guidance for the second quarter. The company expects to earn between 32 and 34 cent... Full story